MOLECULAR PARTNERS ADS/1
MOLECULAR PARTNERS ADS/1
Certificat de dépôt · US60853G1067 · MOLN · A3CSB5 (XNAS)
Aperçu
3,33 EUR
0,02 % 0,0007 EUR
Frankfurt (XNAS) · Cours et graphiques actuels sur MoneyPeak
09.06.2025 14:30

Cours actuels de MOLECULAR PARTNERS ADS/1

BourseTickerDeviseDernier échangeCoursVariation journalière
XNAS: NASDAQ
NASDAQ
MOLN
USD
09.06.2025 14:30
3,80 USD
3,80 USD
+0,02 %

Performance

Jour Semaine Mois 3 mois 6 mois 1 an 5 ans
-0,16 % -0,10 % -11,30 % -22,09 % -38,50 % -11,69 % -80,80 %

Profil de l'entreprise pour MOLECULAR PARTNERS ADS/1 Certificat de dépôt

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Données de l'entreprise

Nom MOLECULAR PARTNERS ADS/1
Société Molecular Partners AG
Symbole MOLN
Site web https://www.molecularpartners.com
Marché d'origine XNAS Frankfurt
WKN A3CSB5
ISIN US60853G1067
Type de titre Certificat de dépôt
Secteur Healthcare
Industrie Biotechnology
PDG Dr. Patrick Amstutz Ph.D.
Capitalisation boursière 147 Mio
Pays Suisse
Devise EUR
Employés 0,2 T
Adresse Wagistrasse 14, 8952 Schlieren
Date d'introduction en bourse 2021-06-16

Symboles boursiers

Nom Symbole
Frankfurt 6ML0.F
NASDAQ MOLN

Autres actions

Les investisseurs qui détiennent MOLECULAR PARTNERS ADS/1 ont également les actions suivantes dans leur portefeuille :
DNO ASA 24/29
DNO ASA 24/29 Obligation
VANECK-GEON.+HEALTHC.1DLA
VANECK-GEON.+HEALTHC.1DLA ETF
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles. Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Mentions légales Protection des données Blog Communauté Retour d'information Changelog
Im App Store herunterladen Bei Google Play herunterladen
Tous droits réservés © LCP GmbH 2025